Sean Jackson

Sean Jackson



20 Queen Street West
Suite 3300
Toronto, ON
M5H 3R3

Sean’s practice is focused on patent litigation where he represents clients from a broad range of industries including the medical products, telecommunications and pharmaceutical industries. Sean has experience representing clients who are asserting their rights as well as those who are defending against allegations of infringement. Sean has appeared before the Federal Court and Federal Court of Appeal. Dr. Jackson’s background in biochemistry and biomedical science allows him to merge science and law into creative solutions addressing his clients’ needs.

Dr. Jackson holds a Ph.D. in biochemistry and biomedical sciences from McMaster University where he studied platelet signaling pathways involved in regulating blood coagulation. Dr. Jackson was awarded numerous scholarships and awards for his research including the prestigious Canadian Institute for Health Research Doctoral Canada Graduate Scholarship.

During law school Sean was the top student in the Intellectual Property Intensive Program at Osgoode Hall Law School. Sean also obtained the top mark in Patent Law and regularly contributed Osgoode’s IPilogue. During his final year of law school Sean completed an internship at a leading Canadian pharmaceutical company.


  • Osgoode Hall Law School, J.D.
  • McMaster University, Ph.D.
  • McMaster University, H.B.Sc. (Summa Cum Laude)

Representative Work

  • Successfully defended W.L. Gore & Associates Inc. against a claim of patent infringement regarding prosthetic vascular graft and stent graft technology (T-2105-13).
  • Successfully represented Teva Canada Limited in a claim for damages under the PM(NOC) Regulations regarding the drug pregabalin (2017 FC 332).
  • Successfully represented Teva Canada Limited in a claim for damages under the PM(NOC) Regulations regarding the drug olanzapine (2017 FC 88).
  • Successfully represented Teva Canada Limited in a claim for damages under the PM(NOC) Regulations regarding the drug venlafaxine (2017 FC 526 on remand from 2016 FCA 161 var’g 2014 FC 248 and 2014 FC 634).
  • Represented Teva Canada Limited in a patent infringement and validity action involving the drug tenofovir (T-1529-12, T-1888-15).
  • Acted for Kudelski S.A., OpenTV Inc. and NAGRAVISION S.A. in a patent infringement action (T-262-17).


  • Jackson, S.G. NoQuid, No Quo: Viagra Patent Held Void for Non-Disclosure. Intellectual Property Journal. (2012) 25(1), pp. 1-11.
  • Nguyen, Y.,Jackson, S.G., Aidoo, F., Junop, M.S. and Burrows, L.L.  Structural characterization of novel Pseudomonas aeruginosa type IV pilins.  Journal of Molecular Biology. (2010) 395491-503.
  • Jackson, S.G.,Al-Saigh, S., Schultz, C. and Junop, M.S.  Inositol pentakisphosphate isomers bind PH domains and inhibit phosphoinositide interactions. BMC Structural Biology. 2011 Feb 10;11:11.
  • Jackson, S.G., Sugiman-Marangos, S., Cheung, K. and Junop, M.S.  Crystallization and preliminary diffraction analysis of truncated human pleckstrin. 2010. Acta Crystallographic Sec F. 2011 Mar 1;67(Pt 3):412-6.
  • Jackson, S.G.,Junop, M.S. and Berti, P.  Evidence for Kinetic Control of Ligand Binding and Staged Product Release in MurA (Enolpyruvyl-UDP-GlcNAc Synthase)-Catalyzed Reactions.  Biochemistry 2009, 4811715-11723.
  • JacksonG., Zhang, Y., Haslam, R.J. and Junop, M.S. (2007). Structural analysis of the carboxy terminal PH domain of pleckstrin bound to D-myo-inositol 1,2,3,5,6-pentakisphosphate. BMC Structural Biology. 2007 Nov 22;7(1):80.
  • Jackson, S.G., Zhang, Y., Bao, X., Zhang, K., Summerfield, R., Haslam, R. J. and Junop, M.S. Structure of the carboxy-terminal PH domain of pleckstrin at 2.1 Å.  Acta Crystallographica Section D. (2006). D62, 324-330.
  • Summerfield, R., Daigle, D., Mayer, S., Mallik, D., Hughes, D., Jackson, S., Sulek, M., Organ, M., Brown, E. and Junop, M. (2006) A 2.13 angstrom structure of E. coli DHFR bound to a novel competitive inhibitor reveals a new binding surface involving the M20 loop Region.  Med. Chem., 49(24): 6977-6986.